- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07772167
Identifying Multidimensional Signatures of Gastric Interoception in Functional Dyspepsia (IMAGINE)
14 de agosto de 2026 atualizado por: Helen Burton-Murray, PHD, Massachusetts General Hospital
This study is being conducted to investigate gut-brain communication in individuals with functional dyspepsia and anorexia nervosa.
The hope is that what the investigators learn from this study will improve the understanding the conditions better to improve treatments.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
150
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Caroline Adams
- Número de telefone: 617-643-7884
- E-mail: imaginestudy@mgb.org
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General Hospital
-
Contato:
- IMAGINE Study Coordinator CRC
- Número de telefone: 617-643-7884
- E-mail: imaginestudy@mgb.org
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Sim
Descrição
Participant Inclusion Criteria--
Functional Dyspepsia Group:
- Males and females; ages 18-65 years
- Rome V functional dyspepsia post-prandial distress syndrome subtype
- Negative upper endoscopy or upper GI series to rule out structural/organic cause for FD
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Fluent in English
- Willing and able to provide informed consent
- Stable dose for 30 days prior to Visit 1 if on a neuropsychiatric medication (e.g., TCA, SNRI, SSRI mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)
- No current plans to initiate a new or change dosing on a neuropsychiatric medication within the study period
Anorexia Nervosa Group:
- Males and females; ages 18-65 years
- DSM-5 anorexia restricting-type by the Eating Disorder Module in the Diagnostic Interview for Mood, Anxiety, and OCD and related Neuropsychiatric Disorders (DIAMOND)
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Fluent in English
- Willing and able to provide informed consent
- Stable dose for 30 days prior to Visit 1 if on an SSRI
- No current plans to initiate a new neuromodulator
- No current plans to initiate a new SSRI or change dosing on an SSRI
Healthy Controls:
- Males and females; ages 18-65 years
- BMI greater than or equal to 18.5 kg/m2
- Fluent in English
- Willing and able to provide informed consent
Participant Exclusion Criteria--
Functional Dyspepsia Group:
Presence of other conditions that could explain the patient's symptoms by medical chart:
- Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT)
- Active H.pylori (by CLO test or stool antigen test)
- Active inflammatory bowel disease
- Eosinophilic gastroenteritis or eosinophilic esophagitis
- Acute renal failure
- Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis
- Acute liver failure
- Any acute gastrointestinal process
- Any plausible structural or metabolic causes
- Heartburn as predominant symptom
- History of peptic ulcer
- Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- History of weight/shape-based eating disorder including anorexia nervosa by DIAMOND
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by modified DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
Anorexia Nervosa Group:
- Diagnosis of chronic gastrointestinal disorder
- Rome V functional dyspepsia
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
- Current use of neuropsychiatric medication other than an SSRI (e.g., TCA, SNRI, mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)
Healthy Controls:
- Diagnosis of chronic gastrointestinal or pain disorder
- Rome V functional dyspepsia
- greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
- Current use of a medication known to influence gastric sensorimotor functions (including neuromodulators and SSRIs)
- Active psychiatric disorder including a feeding/eating disorder by DIAMOND
- Endorses any contraindications to MRI
- Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
- Allergy to pineapple (used in the test meal during MRI)
- History of GI tract surgery or any serious medical condition (e.g., cancer)
- Pregnancy/breastfeeding within the last 8 weeks
- Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
- Narcotic analgesics greater than three days per week
- Cannabinoid use greater than three days per week
- Intellectual disability by history
- Illiteracy
- Current binge eating by DIAMOND
- Current self-induced vomiting by DIAMOND
- Current laxative or diuretic misuse by DIAMOND
- Current substance/alcohol use disorder within past year by DIAMOND
- Current/history of psychosis by DIAMOND
- Current mania by DIAMOND
- Active suicidal ideation by DIAMOND modified suicide module; passive suicidal ideation is allowed
- Inability or unwillingness to consume food by mouth
- Inability to provide informed consent
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Functional Dyspepsia, Healthy Control, Anorexia Nervosa
|
Pineapple pudding snack, with pre- and post-snack fMRI
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Visual interoception task
Prazo: Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
|
The study team will be investigating brain activity and connectivity during an interoception task.
This will be measured via functional magnetic resonance imaging (fMRI) which is able to measure blood flow to regions of the brain.
|
Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
|
|
Resting state connectivity
Prazo: Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
|
Change in brain activity during rest pre and post prandially using functional magnetic resonance imaging (fMRI).
|
Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
|
|
Gastric peristaltic velocity
Prazo: 30 minutes (only in Visit 2, within approximately two weeks of Visit 1)
|
MRI-derived gastric motility outcome
|
30 minutes (only in Visit 2, within approximately two weeks of Visit 1)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Helen Burton-Murray, PhD, Massachusetts General Hospital
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
16 de março de 2026
Conclusão Primária (Estimado)
1 de março de 2030
Conclusão do estudo (Estimado)
1 de março de 2031
Datas de inscrição no estudo
Enviado pela primeira vez
29 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
14 de agosto de 2026
Primeira postagem (Real)
19 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
19 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
14 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2025P001856
- R01DK145599 (Concessão/Contrato do NIH dos EUA)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .